Abstract
We share our experience with biological agents in children with juvenile idiopathic arthritis with an aim to highlight the adverse events and response to treatment. Out of a total of 10 children treated with biological agents, one patient had serious infection, all showed good response and none had tuberculosis. High cost was limiting factor for their use.
MeSH terms
-
Abatacept / therapeutic use
-
Adolescent
-
Antibodies, Monoclonal, Humanized / therapeutic use
-
Antirheumatic Agents / therapeutic use*
-
Arthritis, Juvenile / drug therapy*
-
Child
-
Child, Preschool
-
Etanercept / therapeutic use
-
Female
-
Humans
-
Infant
-
Male
-
Treatment Outcome
Substances
-
Antibodies, Monoclonal, Humanized
-
Antirheumatic Agents
-
Abatacept
-
tocilizumab
-
Etanercept